



## DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

I, Stephen Venson O'Quinn, c/o Glaxo Wellcome Inc., doing business in Research Triangle Park, North Carolina, USA, and Roger K. Cady, residing in Ozark, Missouri, USA, Donna Lee Gutterman, c/o Glaxo Wellcome Inc., doing business in Research Triangle Park, North Carolina, USA, respectively, declare that we are citizens of the United States of America and that we believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled:

### **Preemptive Prophylaxis of Migraine**

that was filed on May 22, 2000 as U.S. Serial No. 09/575,277.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims.

We acknowledge the duty to disclose to the Patent and Trademark Office all information known to be material to patentability as defined in §1.56. We acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

We hereby claim priority benefits under Title 35, United States Code, §120 of co-pending U.S. Application No. 09/185,310, filed 3 November 1998.

There is no foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

We hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, we acknowledge the duty to disclose all information known to us to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>09/185,310</u>	<u>3 November 1998</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status)

We hereby appoint Robert E. Muir, Patent Office Reg. No. 23,017, telephone number 309-637-4900, Richard J. Musgrave, Patent Office Reg. No. 44,960, telephone number 309-637-4900, Kevin M. Kercher, Patent Office Reg. No. 33,408, telephone number 309-637-4900, and H. Frederick Rusche, Patent Office Reg. No. 45,061, telephone number 314-421-4800, our attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected with this application. Please address all correspondence to:

**Robert E. Muir, Esq.  
Husch & Eppenberger, LLC  
401 Main Street, Suite 1400  
Peoria, IL 61602-1241**

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

x 


Roger K. Cady  
631 Riverview Road  
Ozark, MO 65721 USA

9-11-00  
Date

x 

Donna Lee Gutterman  
c/o Glaxo Wellcome Inc.  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398

15 AUG 00  
Date

x 

Stephen Venson O'Quinn  
c/o Glaxo Wellcome Inc.  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398

22 AUG 00  
Date